Patentee Secures Reversal of JMOL on Written Description and Enablement for Method of Treatment by Administering Genus of Antibodies at Federal Circuit

Why It Matters

The ruling strengthens patent protection for therapeutic methods that rely on a class of well‑known biologics, giving innovators greater certainty in the migraine market. It also signals tighter scrutiny of written‑description and enablement arguments in biotech patents.

Key Takeaways

• Federal Circuit reversed JMOL, upholding method-of-treatment claims
• Court held single antibody disclosure satisfies written description for genus
• Enablement met because all anti‑CGRP antibodies treat headaches
• Decision distinguishes broad functional claims from indication‑specific method claims

Pulse Analysis

Anti‑CGRP antibodies have become a cornerstone of modern migraine therapy, with several biologics approved in the United States and Europe. Patent portfolios around these antibodies often include both composition claims and method‑of‑treatment claims, the latter targeting the clinical use of a broad class of molecules. In Teva v. Lilly, the Federal Circuit examined whether a patent that described only one humanized antibody could claim the entire genus for treating headaches. By emphasizing the routine nature of antibody humanization and the predictable therapeutic effect across the class, the court affirmed the robustness of method claims even when the underlying molecules are well known.

The decision revisits two core patent doctrines: written description and enablement. Historically, courts have required a detailed disclosure to support a claimed genus, as seen in the Amgen case where the lack of specific examples led to invalidation. Here, the Federal Circuit differentiated the claims, noting they were not directed to the antibodies themselves but to their use in a specific indication. The court concluded that a skilled artisan could infer from the specification that all anti‑CGRP antagonists would alleviate headaches, satisfying both statutory requirements without needing exhaustive exemplars.

For the pharmaceutical industry, the ruling offers a roadmap for drafting stronger method‑of‑treatment patents. Companies can leverage a single exemplary embodiment, provided they clearly articulate the functional relationship between the biologic class and the therapeutic outcome. This approach may reduce the burden of generating extensive experimental data for each antibody variant, accelerating patent prosecution and fortifying enforcement strategies. However, litigants must still be prepared to demonstrate that the claimed therapeutic effect is predictable across the genus, lest future courts revert to stricter disclosure standards.